Navigation Links
Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
Date:10/10/2011

nds towards benefit for lung function measures. The Forced Expiratory Volume in one second (FEV1) decreased in the placebo group as compared to baseline at 26 weeks (change: -5.6%; p=0.0582) with no such deterioration being observed in the AIMSPRO treated group. Similarly, the Forced Vital Capacity (FVC) was observed to decrease in the placebo group as compared to baseline at 26 weeks (change: -5.6%, p=0.1038), but not in the AIMSPRO treated group, where the FVC showed an increase (change:+1.8%, p=0.3225).

"Although requiring further confirmatory studies, these results are quite exciting, especially when compared to what has been seen in other pilot trials in scleroderma as there is a clear unmet medical need for patients suffering with this life-threatening disease" said Professor Christopher Denton, Professor of Experimental Rheumatology at the Royal Free Hospital in London, United Kingdom, the principal investigator for the trial. "The important value of the safety data from such a well-conducted trial in such a serious disease is clear, apart from the signals of therapeutic benefit."

Daval's Clinical and Scientific Director, Professor Syed Haq commented, "This study, conducted at one of the world's leading scleroderma centres, was an important first step towards understanding whether AIMSPRO could significantly help patients with diffuse scleroderma and potential overlapping connective tissue disorders, for which there is no cure, by arresting the disease even in its latter stages. AIMSPRO has been shown to be well-tolerated and safe and with the several positive therapeutic signals demonstrated, some of which were significant, it certainly warrants further investigation on a larger scale to determine the full efficacy of AIMSPRO in Late Stage Established Diffuse Cutaneous Systemic Sclerosis."

At the completion of the 26 week period of the study, AIMSPRO was offered to the patients on a compassionate
'/>"/>

SOURCE Daval International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
(Date:4/23/2015)... 2015 /CNW/ - Health Canada is working with the ... the safety information regarding the risk of serious cardiovascular ... products are used at high doses (at or above ... of use. Ibuprofen is a non-steroidal anti-inflammatory ... to reduce inflammation. The majority of ibuprofen products in ...
(Date:4/23/2015)... , Apr. 23, 2015 Surna, Inc. ... and distributes state-of-the art equipment and systems for ... commercial indoor cannabis cultivation, will host a shareholder ... April 27, 2015, at 4:15 PM Eastern Standard ... The conference call will be listen-in only, but ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
... July 9 The companies jointly announce the ... the Greek language version of the GeneMedRx drug and gene ... include hundreds of drugs used exclusively in Greece , ... user interface. Both the English and Greek versions of GeneMedRx ...
... HAMILTON , Canada , July ... to,reduce the incidence of venous thromboembolism in orthopedic surgery patients,in a ... McMaster University professor Dr. Alexander Turpie . , ... ...
Cached Medicine Technology:Medigene Appointed Exclusive Greek Licensee for GeneMedRx Personalized Prescribing Software 2Drug Study Shows Improvement in Major Orthopedic Surgery Care 2
(Date:4/25/2015)... 2015 The URO CENTER of NEW YORK ... chosen by the New York Academy of Medicine to receive ... the field of Urology. , Dr. Ferdinand Valentine, born in ... diseases. He was a man of rare and attractive ... Not only did he devote his life to his ...
(Date:4/24/2015)... Constellations Recovery celebrates the opening of ... Just 35 miles from New York City, Constellations Recovery ... life while recovering from addiction. The Open House, which ... therapists, doctors and treatment centers to see the residence, ... opportunities offered by Constellations Recovery.,  , The newly opened ...
(Date:4/24/2015)... April 24, 2015 The Fastest Fat Loss ... their great success of the Xtreme Fat Loss Diet, has ... The fat loss blueprint that claims to help one lose ... of HealthyandFitZone.com's Stan Stevenson, prompting an investigative review. , "Our ... the creators spent years researching and experimenting with these methods ...
(Date:4/24/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining how ... citizens . , Senior citizens may be considered ... they cannot find affordable coverage. By comparing online auto ... coverage for their cars at the best prices. ... provides free leads from various agencies that are in ...
(Date:4/24/2015)... “Kind,” “selfless,” “the voice of reason” and ... Weiner described pediatric oncology nurse Laura Vasquez of Children’s ... during her five-year battle with a malignant brain tumor. ... and numerous experimental treatments, Vasquez continued caring for Alexa, ... was not in the hospital and even sitting vigil ...
Breaking Medicine News(10 mins):Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Low Cost Auto Insurance Quotes for Senior Citizens 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4
... New web-based research has quantified the attractiveness of the ... features of one woman into 243 variations with differing ... widths. Then more than 34,000 people judged the attractiveness ... the same in all of the photos, researchers found ...
... Old Republic International Corporation (NYSE: ORI ... the payment of the regular quarterly cash dividend of 17 ... March 13, 2009 to shareholders of record on March 4, ... rate initially approved for the second quarter of 2008. ...
... as Asian AffiliateNEW YORK and SINGAPORE, Feb. 26 ... prevention services, has signed an affiliation agreement with ... group based in Singapore and a subsidiary of ... medicine programs throughout Asia. Under the agreement, ParkwayHealth ...
... 274 adults with intellectual disabilities currently receiving funding ... , Washington, DC(February 23, 2009)The Supports Intensity ... for people with intellectual disability based on individual ... tool, unlike adaptive behavior instruments or other measures ...
... at the UCSF-Gladstone Institute for Virology and Immunology Center ... development of the next generation of HIV/AIDS researchers and ... published in the American Journal for Public Health ... of the AJPH website, the program focuses on overcoming ...
... Abbott ( NYSE: ABT ),today announced that it has ... now a wholly owned subsidiary of Abbott and has been,renamed ... acquisition of AMO enhances and strengthens Abbott,s diverse mix of,medical ... large and,growing eye care market. Abbott Medical Optics holds ...
Cached Medicine News:Health News:Plastic and reconstructive surgery ... in brief 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 3Health News:Supports Intensity Scale is effective for identifying needs in people with intellectual disability 2Health News:Effective mentoring critical to HIV/AIDS research efforts 2Health News:Abbott Completes Acquisition of Advanced Medical Optics 2
... Used for stone manipulation ... tract. Enhanced wire strength permits ... ureter more readily than standard ... facilitates easy, ergonomic one-handed operation. ...
... for stone manipulation and ... tract. Enhanced wire strength ... in the ureter. The ... ergonomic one-handed operation. Supplied ...
... Used to establish and maintain ... ureteral segment promotes patency and allows ... subsides. Supplied sterile in peel-open packages. ... evaluation is advised; stent must not ...
... Used to prevent ... allow renal drainage after ... in peel-open packages. Intended ... Periodic evaluation is advised; ...
Medicine Products: